FDA Approved: DEXILANT — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Dexilant (lansoprazole) filed by Takeda, extending its labeling with additional indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Erosive Esophagitis
• Gastric Ulcer
• Gastroesophageal Reflux Disease
• Helicobacter Pylori Infection
• Zollinger-ellison Syndrome

Drugs mentioned

• Dexilant (dexlansoprazole)

Snippet

SUPPL AP for DEXILANT (DEXLANSOPRAZOLE)